Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience.
Urbizu
J M
JM
Department of Nephrology, Hospital de Cruces, Barakaldo, Bizkaia, Spain.
Amenabar
J J
JJ
Gomez-Ullate
P
P
Zarraga
S
S
Lampreabe
I
I
D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D017582:Renal Replacement Therapy; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors; D017211:Treatment Failure
D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus